##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 81 Download : 84

##plugins.themes.academic_pro.article.main##

Abstract

The aim is to study of heart’s structure and hemodynamic indicators according to composition of metabolic syndrome components in the patient with chronic heart failure (CHF)functional class (FC) IIIII. 62 men-patient with cardiosclerosis after heart attack were examined by the way of echocardiography on CHF FC II-III (NYHA). According to metabolic syndrome components they are devided into 3 groups: 1 st group (n=20), patients without signs of metabolic syndrome; 2nd group (n=21) patients with combination of dyslipidemia (DLP), abdominal obesity (AO), arterial hypertenion (AG) and hypertriglyceridemia; 3rd group (n=21) with different combination of dyslipoproteinemia, diabetes and obesity also AG and hypertriglyceridemia. in CHF passed with metabolic syndrome is seen a clear sign of heart’s systolic and diastolic.the presence of metabolic syndrome in CHF also its progressing is the subject to be hypertrophy of left ventricle, breaking the transmitral blood flow, also thickening of barier between ventricles and left ventricle back thickness

Keywords

chronic heart failure metabolic syndrome echocardiography

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Atakhodjaeva Gulchekhra Abdunabievna, Azamov Ramozon To’lqin o’g’li, & Akbarova Gulchexra Muradovna. (2023). The Role of Metabolic Syndrome in The Nature of Postinfarction Remodeling of The Heart in Patients with Chronic Heart Failure. Texas Journal of Medical Science, 24, 27–30. https://doi.org/10.62480/tjms.2023.vol24.pp27-30
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Agostoni P, Paolillo S, Mapelli M, et al. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. European Journal of HeartFailure. 2018;20:700-10. doi:10.1002/ejhf.989.
  2. Alyavi B.A. Teaching aid. Metabolic syndrome.15-33. (2016)
  3. Atakhodjaeva G.A. Аnti-remodeling efficiency of preparations such as perindopril, veroshpiron and bisoprolol applied to patients with diastolic chronic heart failure and metabolic syndrome //EUROPEAN SCIENCE REVIEW 2017 11-12, Австрия, Вена (57-61)
  4. Atakhodjaeva G., Mizaeva B., Aripova J., Abdulatipov A., Valiev A. The effectiveness of the treatment of heart failure metabolic syndrome on the parameters of post infarct remodeling and functional state of the left ventricle in patients with metabolic syndrome. Chin J Ind Hyg Occup Dis, 2021，Vol.39， No.13 Р. 382-392. https://doi.org/10.5281/zenodo.5593953
  5. Atakhodjaeva Gulchekhra Abdunabievna, Aripova Jamilya Shukhratovna THE STATE OF ENDOTHELIAL FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE WITH VARIOUS MANIFESTATIONS OF THE METABOLIC SYNDROME //第 49 卷第 08 期 2022 年 月 湖南大学学报（自然科学版） Journal of Hunan University (Natural Sciences, Vol. 49. No. 08 August 2022
  6. Polyakov D.S., Fomin I.V., Vanikulova F.Y. and others.
  7. Epidemiological program EPOCH - CHF: decompensation of chronic heart failure in real clinical practice (EPOCH-D - CHF). Journal of Heart Failure. 2016;17 (5):299–305.
  8. ESC recommendations for the diagnosis and treatment of acute and chronic heart failure 2016 (selected provisions)//Ліки України - Medicine of Ukraine. - 2016. - №7-8 (203-204). – С. 8-12.
  9. Working Group on the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) With the participation of: Association of Heart Failure (ASH) as part of ESC // Russian Journal of Cardiology. -2017. - №1 (141). - С7-81.
  10. AlFaleh H, Elasfar AA, Ullah A, AlHabib KF, Hersi A, Mimish L et al. Worsening heart failure in «real-world» clinical practice: predictors and prognostic impact: WHF in «real-world» clinical practice. European Journal of Heart Failure. 2017;19 (8):987–95.
  11. Damman K., Gori M., Claggett B. et al. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail. 2018.
  12. Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function: Impaired contractility in iron-deficient cardiomyocytes. European Journal of Heart Failure. 2018;20 (5):910–9.
  13. Lipska KJ. Metformin Use in Patients With Historical Contraindications. Annals of Internal Medicine. 2017;166 (3):225.
  14. Kamilova U.К., Rasulova Z.D., Ibabaekova Sh.R., Nurmamatova D.B. Effect of lisinopril and losartan on the processes of cardiovascular remodeling and renal function in patients with chronic heart failure. // Cardiology Uzbekistan. 2014;3:18-22.